A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented. At the conclusion of this course, participants will be able to: - Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT - Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice - Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging - Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era.

A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented. At the conclusion of this course, participants will be able to: - Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with a specific focus on DOTA, PSMA, and PRRT - Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice - Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging - Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era.